

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5157759

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	JOHNSON MATTHEY PLC	04/16/2018
RECEIVING PARTY DATA		
Name:	ALDEYRA THERAPEUTICS, INC.	
Street Address:	131 HARTWELL AVENUE	
Internal Address:	SUITE 320	
City:	LEXINGTON	
State/Country:	MASSACHUSETTS	
Postal Code:	02421	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	15924005
CORRESPONDENCE DATA		
Fax Number:	(617)426-6567	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	617-728-7100	
Email:	BOSPatents@dechert.com	
Correspondent Name:	DECHERT LLP	
Address Line 1:	ONE INTERNATIONAL PLACE, 40TH FLOOR	
Address Line 2:	100 OLIVER STREET	
Address Line 4:	BOSTON, MASSACHUSETTS 02110-2605	
ATTORNEY DOCKET NUMBER:	393471-014US (159387)	
NAME OF SUBMITTER:	DONALD V. SCALTRITO	
SIGNATURE:	/Donald V. Scaltrito/	
DATE SIGNED:	09/25/2018	
Total Attachments: 3		
source=2018-09-24_Aldeyra_159387_Assignment_JohnsonMatthey-Aldeyra#page1.tif		
source=2018-09-24_Aldeyra_159387_Assignment_JohnsonMatthey-Aldeyra#page2.tif		
source=2018-09-24_Aldeyra_159387_Assignment_JohnsonMatthey-Aldeyra#page3.tif		

ASSIGNMENT

WHEREAS, we, the undersigned, **JOHNSON MATTHEY PLC**, having a place of business at **Pharmorphix, 250 Cambridge Science Park, Milton Road, Cambridge CB4 0WE, UNITED KINGDOM** (hereinafter termed "Assignor"), owner of an interest in the right, title and interest in and to certain new and useful improvements disclosed in **"POLYMORPHIC COMPOUNDS AND USES THEREOF"**, for which a United States Patent Application having Application No. **15/924,005**, filing date of **March 16, 2018**, and for which a provisional U.S. patent application having Application No. **62/472,478** was filed **March 16, 2017**, and for which a provisional U.S. patent application having Application No. **62/519,331** was filed **June 14, 2017**, by virtue of a prior assignment from inventors **Amanda BUIST, Osama SULEIMAN and Kate WITTERING** (hereinafter termed "Inventors"), and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries;

WHEREAS, **ALDEYRA THERAPEUTICS, INC.**, having a place of business at **131 Hartwell Avenue, Suite 320, Lexington, MA 02421, USA**, (hereinafter termed "Assignee"), is desirous of acquiring Assignor's entire right, title and interest in and to said application and the invention disclosed therein, and in and to all embodiments of the invention, heretofore conceived, made or discovered by said Inventors (all collectively hereinafter termed "said invention"), and in and to any and all patents, inventor's certificates and other forms of protection (hereinafter termed "patents") thereon granted in the United States and foreign countries.

NOW, THEREFORE, in consideration of good and valuable consideration, acknowledged by said Assignor to have been received in full from said Assignee:

1. Said Assignor does hereby sell, assign, transfer and convey, and/or confirm prior sale, assignments, transfer, and conveyance, unto said Assignee, Assignor's entire right, title and interest (a) in and to said application and said invention; (b) in and to all rights to apply for foreign patents on said invention pursuant to the International Convention for the Protection of Industrial Property or otherwise; (c) in and to any and all applications filed and any and all patents granted on said invention in the United States or any foreign country, including each and every application filed and each and every patent granted on any application which is a division, substitution, or continuation of any of said applications; and (d) in and to each and every reissue or extensions of any of said patents.


2. Said Assignor hereby covenants and agrees to cooperate with said Assignee to enable said Assignee to enjoy to the fullest extent the right title and interest herein conveyed in the United States and foreign countries. Such cooperation by said Assignor shall include reasonable production of pertinent facts and documents, giving of testimony, execution of petitions, oaths, specifications, declarations or other papers, and other reasonable assistance to the Assignee (a) for perfecting in said Assignee the right, title and interest herein conveyed; (b) for prosecuting any of said applications; (c) for filing and prosecuting substitute, divisional, continuing or additional applications covering said invention; (d) for filing and prosecuting applications for reissuance of any said patents; (e) for interference or other priority proceedings involving said invention; and (f) for legal proceedings involving said invention and any applications therefore and any patents granted thereon, including without limitation opposition proceedings, cancellation proceedings, priority contests, public use proceedings, infringement actions and court actions; provided, however, that any expense incurred by said Assignor in providing such cooperation shall be paid for by said Assignee.

3. The terms and covenants of this assignment shall inure to the benefit of said Assignee, its successors, assigns and other legal representatives, and shall be binding upon said Assignor, their respective heirs, legal representatives and assigns.

The undersigned, whose title is supplied below, is authorized to act on behalf of the assignor.

Date: 16 APR 13


Assignor: JOHNSON MATTHEY PLC

Signed: 

Print Name: CRAIG W. GRANT

Print Title: SITE DIRECTOR

Address: Pharmorphix, 250 Cambridge Science Park,
Milton Road, Cambridge CB4 0WE, UNITED
KINGDOM

Witness: 
DONNA TUCKER

Witness: E Radley
ELIZABETH RADLEY

Date: 09/18/2018

Assignee: ALDEYRA THERAPEUTICS, INC.

Signed: 

Print Name: TODD BRADY

Print Title: CEO

Address: 131 Hartwell Avenue, Suite 320, Lexington,
MA 02421, USA

Witness: 

Witness: _____